BioNTech SE BNTX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -16.44% | -58.50% | -28.17% | -16.73% | 29.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.44% | -58.50% | -28.17% | -16.73% | 29.76% |
| Cost of Revenue | -38.99% | 30.11% | -5.27% | 35.80% | -11.85% |
| Gross Profit | -14.00% | -95.22% | -47.55% | -30.24% | 36.74% |
| SG&A Expenses | 18.34% | 47.53% | 39.02% | 80.14% | 4.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -92.70% | 695.93% | 285.92% | 355.39% | 107.93% |
| Total Operating Expenses | -38.94% | 41.99% | 23.72% | 28.10% | 25.92% |
| Operating Income | 451.44% | -102.91% | -41.44% | -308.49% | 254.65% |
| Income Before Tax | 784.86% | -118.52% | -41.81% | -182.45% | -83.45% |
| Income Tax Expenses | -30.86% | -141.24% | -35.97% | 103.22% | 244.13% |
| Earnings from Continuing Operations | 732.90% | -117.58% | -42.23% | -228.35% | -115.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 732.90% | -117.58% | -42.23% | -228.35% | -115.41% |
| EBIT | 451.44% | -102.91% | -41.44% | -308.49% | 254.65% |
| EBITDA | 266.94% | -58.29% | -26.35% | -204.75% | 215.77% |
| EPS Basic | 707.06% | -107.52% | -34.96% | -226.40% | -115.56% |
| Normalized Basic EPS | 325.49% | -103.91% | -30.11% | -167.13% | -44.38% |
| EPS Diluted | 698.86% | -107.52% | -34.96% | -226.70% | -115.76% |
| Normalized Diluted EPS | 319.73% | -103.91% | -30.11% | -167.13% | -43.70% |
| Average Basic Shares Outstanding | 4.25% | 4.85% | 5.38% | 1.55% | -1.00% |
| Average Diluted Shares Outstanding | 5.68% | 4.85% | 5.38% | 1.55% | -2.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |